CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 58 enrolled
Drug / intervention
ACRYSOF® IQ PanOptix® Toric Trifocal IOL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04528069
NCT04528069N/ACompleted
CompareCT.gov

Clinical Investigation of the Visual Outcomes and Safety of AcrySof® IQ PanOptix® Toric Trifocal IOLs in an Asian Population

Alcon Research·interventional·Posted Aug 27, 2020·Updated Dec 30, 2022

In Brief

A clinical study evaluating ACRYSOF® IQ PanOptix® Toric Trifocal IOL and Cataract surgery for Aphakia and Corneal Astigmatism. Completed, enrolled 58 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the clinical performance of the ACRYSOF® IQ PanOptix® Toric Trifocal intraocular lens (IOL) when implanted in the eye following cataract removal in an Asian population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Corneal Astigmatism
CountriesAustralia
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 27, 2020
Enrollment StartNov 16, 2020
Primary CompletionDec 17, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.8 years ago

Interventions

ACRYSOF® IQ PanOptix® Toric Trifocal IOLdevice

Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.

Cataract surgeryprocedure

Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use